MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, Inc. announces the formation of a five member Scientific Advisory Board (SAB) for Ocular Therapies. arGentis is currently advancing two transdermal therapies for the treatment of dry eye syndrome (DES) into the clinical development. The transdermal testosterone formulation treats DES in menopausal women, while the transdermal progesterone formulation treats DES in the wider population, including younger women and men. Both therapies are uniquely applied in a cream formulation to the upper and lower eyelid, transdermally delivering the active pharmaceutical ingredient directly to the affected glands. The SAB, which includes some of the foremost experts in dry eye syndrome, clinical trial development and drug formulation, will provide counsel on a broad range of scientific, regulatory, clinical and product development matters.
